KBC Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$243M Buy
4,009,205
+42,084
+1% +$2.45M 0.61% 21
2025
Q4
$214M Sell
3,967,121
-102,790
-3% -$4.94M 0.49% 34
2025
Q3
$184M Buy
4,069,911
+50,342
+1% +$2.35M 0.44% 38
2025
Q2
$186M Buy
4,019,569
+169,974
+4% +$8.34M 0.5% 34
2025
Q1
$235M Sell
3,849,595
-205,273
-5% -$12M 0.73% 19
2024
Q4
$229M Buy
4,054,868
+628,908
+18% +$35.1M 0.63% 22
2024
Q3
$177M Sell
3,425,960
-2,190,367
-39% -$103M 0.54% 30
2024
Q2
$233M Buy
5,616,327
+320,737
+6% +$14.4M 0.7% 21
2024
Q1
$287M Buy
5,295,590
+2,448,190
+86% +$125M 0.91% 17
2023
Q4
$146M Buy
2,847,400
+1,367,151
+92% +$71.8M 0.52% 39
2023
Q3
$85.9M Sell
1,480,249
-676,743
-31% -$41.5M 0.35% 65
2023
Q2
$138M Buy
2,156,992
+656,724
+44% +$44M 0.57% 38
2023
Q1
$104M Sell
1,500,268
-293,580
-16% -$20.7M 0.44% 48
2022
Q4
$129M Sell
1,793,848
-1,032,048
-37% -$77.8M 0.63% 32
2022
Q3
$201M Sell
2,825,896
-275,230
-9% -$20M 1.04% 12
2022
Q2
$239M Buy
3,101,126
+79,629
+3% +$6.06M 1.19% 11
2022
Q1
$221M Buy
3,021,497
+272,853
+10% +$18.3M 0.87% 15
2021
Q4
$171M Buy
2,748,644
+32,810
+1% +$1.92M 0.57% 38
2021
Q3
$161M Sell
2,715,834
-2,373,872
-47% -$156M 0.59% 33
2021
Q2
$340M Buy
5,089,706
+492,098
+11% +$32.1M 0.61% 30
2021
Q1
$290M Buy
4,597,608
+217,818
+5% +$13.6M 0.59% 37
2020
Q4
$1.47B Buy
4,379,790
+968,886
+28% +$59.6M 0.63% 28
2020
Q3
$206M Buy
3,410,904
+353,136
+12% +$21.3M 0.61% 32
2020
Q2
$180M Buy
3,057,768
+2,214,745
+263% +$132M 0.6% 32
2020
Q1
$47M Sell
843,023
-100,257
-11% -$6.13M 0.39% 55
2019
Q4
$60.5M Buy
943,280
+69,199
+8% +$3.96M 0.38% 50
2019
Q3
$44.3M Buy
874,081
+26,347
+3% +$1.24M 0.33% 59
2019
Q2
$38.4M Buy
847,734
+108,964
+15% +$5.08M 0.3% 75
2019
Q1
$35.2M Buy
738,770
+320,896
+77% +$16M 0.29% 79
2018
Q4
$21.7M Buy
417,874
+15,465
+4% +$831K 0.24% 102
2018
Q3
$25M Buy
402,409
+40,566
+11% +$2.41M 0.19% 140
2018
Q2
$20M Sell
361,843
-11,408
-3% -$616K 0.17% 163
2018
Q1
$23.6M Buy
373,251
+51,770
+16% +$3.33M 0.22% 117
2017
Q4
$19.7M Sell
321,481
-151,287
-32% -$9.46M 0.17% 158
2017
Q3
$30.1M Buy
472,768
+51,583
+12% +$3.01M 0.27% 92
2017
Q2
$23.5M Sell
421,185
-441,854
-51% -$24M 0.23% 112
2017
Q1
$46.9M Buy
863,039
+539,164
+166% +$29.6M 0.42% 53
2016
Q4
$18.9M Sell
323,875
-24,830
-7% -$1.36M 0.19% 131
2016
Q3
$18.8M Sell
348,705
-173,681
-33% -$11.2M 0.22% 108
2016
Q2
$38.4M Buy
522,386
+134,184
+35% +$9.48M 0.55% 30
2016
Q1
$24.8M Buy
388,202
+33,045
+9% +$2.08M 0.41% 53
2015
Q4
$24.4M Sell
355,157
-47,977
-12% -$3.17M 0.45% 44
2015
Q3
$23.9M Sell
403,134
-77,427
-16% -$4.91M 0.48% 40
2015
Q2
$32M Buy
480,561
+43,929
+10% +$2.89M 0.41% 51
2015
Q1
$28.2M Sell
436,632
-140,535
-24% -$8.8M 0.36% 71
2014
Q4
$34.1M Buy
577,167
+417,813
+262% +$23.6M 0.41% 57
2014
Q3
$8.16M Sell
159,354
-380,681
-70% -$19M 0.28% 90
2014
Q2
$26.2M Sell
540,035
-197,902
-27% -$9.75M 0.3% 64
2014
Q1
$38.3M Buy
737,937
+55,279
+8% +$2.94M 0.61% 29
2013
Q4
$36.3M Sell
682,658
-97,457
-12% -$4.96M 0.55% 31
2013
Q3
$36.1M Buy
780,115
+259,717
+50% +$11.4M 0.58% 28
2013
Q2
$23.3M Buy
+520,398
New +$22.6M 0.43% 47

Other funds holding BMY

KBC Group's BMY Position: Q1 2026 in Review

KBC Group increased its Bristol-Myers Squibb (BMY) stake by 1.1% in Q1 2026, buying an estimated $2.45M and bringing the position to 4,009,205 shares worth $243M. The position accounts for 0.61% of the portfolio, ranked #21.

KBC Group first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.47B in Q4 2020. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • KBC Group held 4,009,205 shares of Bristol-Myers Squibb worth $243M as of Q1 2026.
  • KBC Group bought 42,084 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.45M.
  • Bristol-Myers Squibb made up 0.61% of KBC Group's portfolio in Q1 2026, its #21 holding.
  • KBC Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • KBC Group's Bristol-Myers Squibb position peaked at $1.47B in Q4 2020.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.